{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:10:17Z","timestamp":1792498217577,"version":"4.5.0"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA273924"],"award-info":[{"award-number":["R01CA273924"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA247648"],"award-info":[{"award-number":["U24CA247648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody-drug conjugates (ADCs) combine a tumor antigen-specific monoclonal antibody with a cytotoxic payload via a linker, enabling selective delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. This approach has revolutionized cancer treatment; however, despite these advantages, resistance to ADCs has emerged as a significant barrier to long-term efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this review, we summarize and analyze molecular pathways implicated in ADC resistance across multiple cancer types, including triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, and relapsed\/refractory acute myeloid leukemia. We further examine emerging strategies to overcome resistance, with particular emphasis on combination therapies and the development of next-generation ADCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Accumulating evidence indicates that identifying and targeting key resistance-associated pathways can expand the population of patients who benefit from ADC therapy and extend the therapeutic lifespan of these agents. We highlight representative preclinical studies that have elucidated resistance mechanisms and demonstrate potential approaches to restore or enhance ADC efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Understanding and overcoming ADC resistance is essential as these agents continue to expand into new therapeutic settings. By bridging basic mechanistic insights with translational and preclinical evidence, this review provides a comprehensive framework for addressing ADC resistance and informs future strategies for optimizing cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag020","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:40:43Z","timestamp":1769776843000},"source":"Crossref","is-referenced-by-count":5,"title":["Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-3433","authenticated-orcid":false,"given":"Aki","family":"Inase","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine , Kobe, 650-0017,","place":["Japan"]},{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University , Columbus, OH, 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Kimbara","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine , Kobe, 650-0017,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Imamura","sequence":"additional","affiliation":[{"name":"Timele Clinic , Tokyo, 167-0022,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-5280","authenticated-orcid":false,"given":"Mitch A","family":"Phelps","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University , Columbus, OH, 43210,","place":["United States"]},{"name":"Pelotonia Institute for Immuno-Oncology, OSUCCC - James, The Ohio State University , Columbus, OH, 43210,","place":["United States"]},{"name":"The James Comprehensive Cancer Center, The Ohio State University , Columbus, OH, 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Graduate School of Medicine , Kobe, 650-0017,","place":["Japan"]},{"name":"Cancer Center, Kobe University Hospital , Kobe, 650-0017,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026032309262986200_oyag020-B1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026032309262986200_oyag020-B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2026032309262986200_oyag020-B3","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1002\/jcph.1720","article-title":"Impact of physiologically based pharmacokinetics, population pharmacokinetics and pharmacokinetics\/pharmacodynamics in the development of antibody-drug conjugates","volume":"60","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2026032309262986200_oyag020-B4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026032309262986200_oyag020-B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026032309262986200_oyag020-B6","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B7","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in Triple-Negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"2026032309262986200_oyag020-B8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.annonc.2021.05.797","article-title":"Corrigendum to \u2018ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q\u2019: [annals of oncology 30 (2019) 1821\u20131830]","volume":"32","author":"Jhaveri","year":"2021","journal-title":"Ann Oncol"},{"key":"2026032309262986200_oyag020-B9","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s00277-021-04601-0","article-title":"Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed\/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin","volume":"100","author":"Reinert","year":"2021","journal-title":"Ann Hematol"},{"key":"2026032309262986200_oyag020-B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3109\/10428194.2012.666543","article-title":"Persistence of CD30 expression in hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure","volume":"53","author":"Nathwani","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2026032309262986200_oyag020-B12","doi-asserted-by":"publisher","first-page":"oyae304","DOI":"10.1093\/oncolo\/oyae304","article-title":"Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis","volume":"30","author":"Wang","year":"2025","journal-title":"Oncologist"},{"key":"2026032309262986200_oyag020-B13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.16949","article-title":"Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia","volume":"191","author":"Ryland","year":"2020","journal-title":"Br J Haematol"},{"key":"2026032309262986200_oyag020-B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"2026032309262986200_oyag020-B15","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026032309262986200_oyag020-B16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026032309262986200_oyag020-B17","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4161\/mabs.21697","article-title":"Fourth world antibody-drug conjugate summit: February 29\u2013march 1, 2012, frankfurt, Germany","volume":"4","author":"Beck","year":"2012","journal-title":"MAbs"},{"key":"2026032309262986200_oyag020-B19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2026032309262986200_oyag020-B20","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"2026032309262986200_oyag020-B21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"2026032309262986200_oyag020-B22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1749-6632.2000.tb07044.x","article-title":"DX-8951f: Summary of phase I clinical trials","volume":"922","author":"De Jager","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"2026032309262986200_oyag020-B23","doi-asserted-by":"publisher","first-page":"eadk1894","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci Adv"},{"key":"2026032309262986200_oyag020-B24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"2026032309262986200_oyag020-B25","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of Early-Stage HER2-Positive breast cancer: Phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"2026032309262986200_oyag020-B26","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent High-Grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Modern Pathology"},{"key":"2026032309262986200_oyag020-B27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"2026032309262986200_oyag020-B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.20517\/cdr.2024.06","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"2026032309262986200_oyag020-B29","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J Clin Invest"},{"key":"2026032309262986200_oyag020-B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026032309262986200_oyag020-B31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"2026032309262986200_oyag020-B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43094-024-00590-9","article-title":"Brentuximab vedotin resistance in classic Hodgkin\u2019s lymphoma and its therapeutic strategies: a review","volume":"10","author":"Bera","year":"2024","journal-title":"Futur J Pharm Sci"},{"key":"2026032309262986200_oyag020-B33","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B36","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein\u2013mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2009.07701.x","article-title":"CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma","volume":"146","author":"Takeshita","year":"2009","journal-title":"Br J Haematol"},{"key":"2026032309262986200_oyag020-B38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood.V128.22.752.752","article-title":"Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2019.00749","article-title":"Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells","volume":"10","author":"Liu-Kreyche","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026032309262986200_oyag020-B40","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B41","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody\u2013drug conjugate (ADC) for HER2-Positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"key":"2026032309262986200_oyag020-B42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab\u2013maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B43","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody\u2013drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"2026032309262986200_oyag020-B44","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"2026032309262986200_oyag020-B45","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1080\/10428194.2020.1786553","article-title":"Anti-Apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia","volume":"61","author":"Godwin","year":"2020","journal-title":"Leukemia & Lymphoma"},{"key":"2026032309262986200_oyag020-B46","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","article-title":"Deficient activation of bak and bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML","volume":"37","author":"Haag","year":"2009","journal-title":"Exp Hematol"},{"key":"2026032309262986200_oyag020-B47","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","article-title":"The t(14; 18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile","volume":"99","author":"Huang","year":"2002","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026032309262986200_oyag020-B49","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1080\/10428194.2023.2243531","article-title":"Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models","volume":"64","author":"Kawasaki","year":"2023","journal-title":"Leuk & Lymphoma"},{"key":"2026032309262986200_oyag020-B50","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1182\/blood-2022-157667","article-title":"Retreatment with polatuzumab vedotin in combination with rituximab increases antitumor activity against polatuzumab Vedotin-Resistant DLBCL cells","volume":"140","author":"Kawasaki","year":"2022","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B51","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: Current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J Med Chem"},{"key":"2026032309262986200_oyag020-B52","doi-asserted-by":"publisher","first-page":"e202102001","DOI":"10.1083\/jcb.202102001","article-title":"Lysosome biogenesis: Regulation and functions","volume":"220","author":"Yang","year":"2021","journal-title":"J Cell Biol"},{"key":"2026032309262986200_oyag020-B53","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-Kinase pathway alterations across 19\u202f784 diverse solid tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026032309262986200_oyag020-B54","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody\u2013drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B55","doi-asserted-by":"publisher","first-page":"pgac063","DOI":"10.1093\/pnasnexus\/pgac063","article-title":"SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1","volume":"1","author":"Tomabechi","year":"2022","journal-title":"PNAS Nexus"},{"key":"2026032309262986200_oyag020-B56","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/cancers12030670","article-title":"The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1","volume":"12","author":"Nadal-Serrano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026032309262986200_oyag020-B57","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1541-7786.MCR-21-0545","article-title":"mTOR inhibition and T-DM1 in HER2-positive breast cancer","volume":"20","author":"Casadevall","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2026032309262986200_oyag020-B58","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"2026032309262986200_oyag020-B59","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1158\/1538-7445.AM2018-3914","article-title":"Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers","volume":"78","author":"Hamblett","year":"2018","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B60","doi-asserted-by":"publisher","first-page":"P6-17-13-P6-17-13","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B61","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming resistance to anti\u2013nectin-4 Antibody-Drug conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO-25-01153","article-title":"Efficacy and safety of neoadjuvant TQB2102 in locally advanced or early human epidermal growth factor receptor 2\u2013positive breast cancer: a randomized, Open-Label, multicenter, phase II trial","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026032309262986200_oyag020-B63","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/13543784.2024.2376573","article-title":"Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody\u2013drug conjugate","volume":"33","author":"Edoardo","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2026032309262986200_oyag020-B64","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026032309262986200_oyag020-B65","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and Bystander-Killing effects of Antibody-Drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B66","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026032309262986200_oyag020-B67","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"2026032309262986200_oyag020-B68","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-21-0397","article-title":"Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0169-5002(03)00190-9","article-title":"Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer","volume":"41","author":"Braybrooke","year":"2003","journal-title":"Lung Cancer"},{"key":"2026032309262986200_oyag020-B70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ygyno.2004.06.047","article-title":"A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant\/refractory ovarian cancer","volume":"95","author":"Clamp","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2026032309262986200_oyag020-B71","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/jco.2004.22.90140.4006","article-title":"A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)","volume":"22","author":"O\u2019 Reilly","year":"2004","journal-title":"JCO"},{"key":"2026032309262986200_oyag020-B72","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2026032309262986200_oyag020-B73","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-24-0426","article-title":"Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates losatuxizumab vedotin and depatux-M in glioblastoma models","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B74","doi-asserted-by":"publisher","first-page":"e2107042118","DOI":"10.1073\/pnas.2107042118","article-title":"Uncialamycin-based antibody\u2013drug conjugates: unique enediyne ADCs exhibiting bystander killing effect","volume":"118","author":"Nicolaou","year":"2021","journal-title":"Proc Nat Acad Sci"},{"key":"2026032309262986200_oyag020-B75","doi-asserted-by":"publisher","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"2026032309262986200_oyag020-B76","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B77","doi-asserted-by":"publisher","first-page":"1269012","DOI":"10.3389\/fimmu.2023.1269012","article-title":"Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy","volume":"14","author":"Rausch","year":"2023","journal-title":"Front Immunol"},{"key":"2026032309262986200_oyag020-B78","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jha2.600","article-title":"GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance","volume":"4","author":"Inase","year":"2023","journal-title":"EJHaem"},{"key":"2026032309262986200_oyag020-B79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.chembiol.2008.11.003","article-title":"Involvement of GSK-3 in regulation of murine embryonic stem cell self-renewal revealed by a series of bisindolylmaleimides","volume":"16","author":"Bone","year":"2009","journal-title":"Chemistry & Biology"},{"key":"2026032309262986200_oyag020-B80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm979","article-title":"Maintenance of pluripotency in human and mouse embryonic stem cells through activation of wnt signaling by a pharmacological GSK-3-specific inhibitor","volume":"10","author":"Sato","year":"2004","journal-title":"Nat Med"},{"key":"2026032309262986200_oyag020-B81","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"2026032309262986200_oyag020-B82","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of Antibody-Drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026032309262986200_oyag020-B83","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cmet.2016.11.003","article-title":"Transcription factor EB controls metabolic flexibility during exercise","volume":"25","author":"Mansueto","year":"2017","journal-title":"Cell Metab"},{"key":"2026032309262986200_oyag020-B84","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.3390\/ijms22094796","article-title":"CHIR99021 augmented the function of late endothelial progenitor cells by preventing replicative senescence","volume":"22","author":"Rethineswaran","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026032309262986200_oyag020-B85","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1038\/onc.2014.390","article-title":"Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth","volume":"34","author":"Azoulay-Alfaguter","year":"2015","journal-title":"Oncogene"},{"key":"2026032309262986200_oyag020-B86","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.V130.Suppl_1.1374.1374","article-title":"An mTORC1\/2 kinase inhibitor remarkably enhances the cytotoxicity of gemtuzumab ozogamicin by activating lysosomal function and cell cycle promotion in AML cells","volume":"130","author":"Maimaitili","year":"2017","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B87","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.leukres.2018.09.017","article-title":"An mTORC1\/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function","volume":"74","author":"Maimaitili","year":"2018","journal-title":"Leuk Res"},{"key":"2026032309262986200_oyag020-B88","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12185-019-02701-2","article-title":"An mTORC1\/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells","volume":"110","author":"Mizutani","year":"2019","journal-title":"Int J Hematol"},{"key":"2026032309262986200_oyag020-B89","doi-asserted-by":"publisher","first-page":"150767","DOI":"10.1016\/j.tmrv.2023.150767","article-title":"Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease","volume":"38","author":"Mina-Osorio","year":"2024","journal-title":"Transfus Med Rev"},{"key":"2026032309262986200_oyag020-B90","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1158\/1078-0432.CCR-19-4137","article-title":"A20 and RBX1 regulate brentuximab vedotin sensitivity in hodgkin lymphoma models","volume":"26","author":"Wei","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B91","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B92","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.1992.10.10.1635","article-title":"Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance","volume":"10","author":"Lum","year":"1992","journal-title":"J Clin Oncol"},{"key":"2026032309262986200_oyag020-B93","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-Maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B94","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody\u2013drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"2026032309262986200_oyag020-B95","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.bmcl.2018.10.043","article-title":"Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads","volume":"28","author":"Kumar","year":"2018","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"2026032309262986200_oyag020-B96","doi-asserted-by":"publisher","first-page":"11725","DOI":"10.1182\/blood-2022-165615","article-title":"Updated analyses: safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: a phase Ib\/II study","volume":"140","author":"Arain","year":"2022","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B97","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood-2023-174216","article-title":"A phase I study of venetoclax in combination with inotuzumab ozogamicin for relapsed or refractory ALL in adults","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B98","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or navitoclax in a murine model of human Hodgkin\u2019s lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032309262986200_oyag020-B99","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1535-7163.MCT-18-0743","article-title":"Neutralization of BCL-2\/XL enhances the cytotoxicity of T-DM1 in vivo","volume":"18","author":"Zoeller","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B100","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2006-12-060947","article-title":"Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor \u03baB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells","volume":"110","author":"Ougolkov","year":"2007","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B101","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3892\/or.2016.4565","article-title":"GSK-3 inhibitor inhibits cell proliferation and induces apoptosis in human osteosarcoma cells","volume":"35","author":"Nishimura","year":"2016","journal-title":"Oncol Rep"},{"key":"2026032309262986200_oyag020-B102","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-04-3642","article-title":"Glycogen synthase kinase-3\u03b2 participates in nuclear factor \u03baB\u2013mediated gene transcription and cell survival in pancreatic cancer cells","volume":"65","author":"Ougolkov","year":"2005","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B103","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/bloodadvances.2018016006","article-title":"Aberrant GSK3\u03b2 nuclear localization promotes AML growth and drug resistance","volume":"2","author":"Ignatz-Hoover","year":"2018","journal-title":"Blood Adv"},{"key":"2026032309262986200_oyag020-B104","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-Positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B105","doi-asserted-by":"publisher","first-page":"1556245","DOI":"10.3389\/fphar.2025.1556245","article-title":"Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026032309262986200_oyag020-B106","doi-asserted-by":"publisher","first-page":"714","DOI":"10.37349\/etat.2024.00243","article-title":"Antibody-drug conjugates combinations in cancer treatment","volume":"5","author":"Pretelli","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"2026032309262986200_oyag020-B107","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B108","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"key":"2026032309262986200_oyag020-B109","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026032309262986200_oyag020-B110","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026032309262986200_oyag020-B111","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10147-021-02085-6","article-title":"Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma","volume":"27","author":"Fedorova","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2026032309262986200_oyag020-B112","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2026032309262986200_oyag020-B113","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/pharmaceutics16091146","article-title":"Synergizing immunotherapy and antibody\u2013drug conjugates: new horizons in breast cancer therapy","volume":"16","author":"Pinto","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026032309262986200_oyag020-B114","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B115","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol"},{"key":"2026032309262986200_oyag020-B116","doi-asserted-by":"publisher","first-page":"22357","DOI":"10.1038\/s41598-024-68311-z","article-title":"Antibody\u2013drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"2026032309262986200_oyag020-B117","doi-asserted-by":"publisher","first-page":"OF3","DOI":"10.1158\/2159-8290.CD-NB2015-172","article-title":"Checkpoint inhibitors boost power of antibody\u2013drug conjugate","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"2026032309262986200_oyag020-B118","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2026032309262986200_oyag020-B119","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.7150\/thno.32648","article-title":"Immune targets in the tumor microenvironment treated by radiotherapy","volume":"9","author":"Ozpiskin","year":"2019","journal-title":"Theranostics"},{"key":"2026032309262986200_oyag020-B120","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/0008-5472.CAN-14-1931","article-title":"Tumor radiosensitization by monomethyl auristatin E: Mechanism of action and targeted delivery","volume":"75","author":"Buckel","year":"2015","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B121","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/1535-7163.MCT-18-1302","article-title":"Precision chemoradiotherapy for HER2 tumors using antibody conjugates of an auristatin derivative with reduced cell permeability","volume":"19","author":"Hingorani","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B122","doi-asserted-by":"publisher","first-page":"104270","DOI":"10.1016\/j.critrevonc.2024.104270","article-title":"Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates","volume":"195","author":"Natangelo","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026032309262986200_oyag020-B123","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","journal-title":"J Hematol Oncol"},{"key":"2026032309262986200_oyag020-B124","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology\u2013new tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026032309262986200_oyag020-B125","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann Oncol"},{"key":"2026032309262986200_oyag020-B126","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"2026032309262986200_oyag020-B127","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antib8040056","article-title":"Understanding inter-individual variability in monoclonal antibody disposition","volume":"8","author":"Thomas","year":"2019","journal-title":"Antibodies"},{"key":"2026032309262986200_oyag020-B128","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1158\/1538-7445.AM2025-1794","article-title":"Abstract 1794: preclinical development of TGW101, a first in class click-cleavable ADC with MMAE against non-internalizing pan-carcinoma marker TAG72","volume":"85","author":"Rossin","year":"2025","journal-title":"Cancer Res"},{"key":"2026032309262986200_oyag020-B129","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","article-title":"OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models","volume":"26","author":"Fabre","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B130","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-Targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026032309262986200_oyag020-B131","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2020-142285","article-title":"A first in human study planned to evaluate hdp-101, an anti-BCMA amanitin Antibody-Drug conjugate with a new payload and a new mode of action, in multiple myeloma","volume":"136","author":"Strassz","year":"2020","journal-title":"Blood"},{"key":"2026032309262986200_oyag020-B132","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026032309262986200_oyag020-B133","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1080\/14796694.2025.2596228","article-title":"Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score \u226550%: phase III study design","volume":"21","author":"Reck","year":"2025","journal-title":"Future Oncology"},{"key":"2026032309262986200_oyag020-B134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026032309262986200_oyag020-B135","doi-asserted-by":"publisher","first-page":"TPS3153","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3153","article-title":"TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced\/metastatic solid tumors","volume":"41","author":"Janjigian","year":"2023","journal-title":"JCO"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag020\/66719708\/oyag020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag020\/66719708\/oyag020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag020\/66719708\/oyag020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:26:40Z","timestamp":1774272400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag020\/8455775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag020","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,3]]},"article-number":"oyag020"}}